Research Article

Evaluation of Incidence and Prognosis of COVID-19 in Patients with Nasal Polyps

Volume: 7 Number: 2 June 1, 2022
EN TR

Evaluation of Incidence and Prognosis of COVID-19 in Patients with Nasal Polyps

Abstract

Objective: Coronavirus disease 2019 (COVID-19) is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Type 2 immune response accompanied by type 2 cytokines such as IL-4, IL-5, IL-13, and eosinophilic inflammation, may have a potential protective effect against COVID-19 in chronic rhinosinusitis patients with nasal polyps (CRS + P). In the study, it was aimed to investigation the prevalence and prognosis of COVID-19 in chronic rhinosinusitis patients with nasal polyps (CRS + P).

Materials and Methods: Patients between the ages of 15-65 operated for CRS + P and were compared with the control group in terms of incidence and disease severity.

Results: Covid RT-PCR test was positive in 5.04% of CRS + P patients. This rate was 8.96% in the control group, and the difference between both groups was statistically significant. When the two groups were compared in terms of disease severity, no significant difference was found.

Conclusions: The incidence of COVID-19 was lower in patients with CRS + P. However, further prospective studies are needed to research the relationship between nasal polyp and COVID-19.

Keywords

References

  1. Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1-464. doi:10.4193/Rhin20.600
  2. Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013;131(6):1479-90. doi:10.1016/j.jaci.2013.02.036
  3. Van Bruaene N, Pérez-Novo CA, Basinski TM, et al. T-cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol. 2008;121(6):1435-41. doi:10.1016/j.jaci.2008.02.018
  4. Wang C, Zhang L. Use of biologics in chronic sinusitis with nasal polyps. Curr Opin Allergy Clin Immunol. 2019;19(4):365-372. doi:10.1097/ACI.0000000000000540
  5. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017
  6. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032
  7. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-118. doi:10.1016/j.jaci.2020.04.006
  8. Dong X, Cao YY, Lu XX, et al. Eleven faces of coronavirus disease 2019. Allergy. 2020;75(7):1699-1709. doi:10.1111/all.14289

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Publication Date

June 1, 2022

Submission Date

October 9, 2021

Acceptance Date

February 24, 2022

Published in Issue

Year 2022 Volume: 7 Number: 2

APA
İlhan, N., Demir, D., Delibaş, K., Güven, M., Yılmaz, M. S., & Kara, A. (2022). Evaluation of Incidence and Prognosis of COVID-19 in Patients with Nasal Polyps. Online Turkish Journal of Health Sciences, 7(2), 175-179. https://doi.org/10.26453/otjhs.982252
AMA
1.İlhan N, Demir D, Delibaş K, Güven M, Yılmaz MS, Kara A. Evaluation of Incidence and Prognosis of COVID-19 in Patients with Nasal Polyps. OTJHS. 2022;7(2):175-179. doi:10.26453/otjhs.982252
Chicago
İlhan, Necati, Deniz Demir, Köksal Delibaş, Mehmet Güven, Mahmut Sinan Yılmaz, and Ahmet Kara. 2022. “Evaluation of Incidence and Prognosis of COVID-19 in Patients With Nasal Polyps”. Online Turkish Journal of Health Sciences 7 (2): 175-79. https://doi.org/10.26453/otjhs.982252.
EndNote
İlhan N, Demir D, Delibaş K, Güven M, Yılmaz MS, Kara A (June 1, 2022) Evaluation of Incidence and Prognosis of COVID-19 in Patients with Nasal Polyps. Online Turkish Journal of Health Sciences 7 2 175–179.
IEEE
[1]N. İlhan, D. Demir, K. Delibaş, M. Güven, M. S. Yılmaz, and A. Kara, “Evaluation of Incidence and Prognosis of COVID-19 in Patients with Nasal Polyps”, OTJHS, vol. 7, no. 2, pp. 175–179, June 2022, doi: 10.26453/otjhs.982252.
ISNAD
İlhan, Necati - Demir, Deniz - Delibaş, Köksal - Güven, Mehmet - Yılmaz, Mahmut Sinan - Kara, Ahmet. “Evaluation of Incidence and Prognosis of COVID-19 in Patients With Nasal Polyps”. Online Turkish Journal of Health Sciences 7/2 (June 1, 2022): 175-179. https://doi.org/10.26453/otjhs.982252.
JAMA
1.İlhan N, Demir D, Delibaş K, Güven M, Yılmaz MS, Kara A. Evaluation of Incidence and Prognosis of COVID-19 in Patients with Nasal Polyps. OTJHS. 2022;7:175–179.
MLA
İlhan, Necati, et al. “Evaluation of Incidence and Prognosis of COVID-19 in Patients With Nasal Polyps”. Online Turkish Journal of Health Sciences, vol. 7, no. 2, June 2022, pp. 175-9, doi:10.26453/otjhs.982252.
Vancouver
1.Necati İlhan, Deniz Demir, Köksal Delibaş, Mehmet Güven, Mahmut Sinan Yılmaz, Ahmet Kara. Evaluation of Incidence and Prognosis of COVID-19 in Patients with Nasal Polyps. OTJHS. 2022 Jun. 1;7(2):175-9. doi:10.26453/otjhs.982252

Creative Commons License
 

Online Türk Sağlık Bilimleri Dergisi [Online Turkish Journal of Health Sciences (OTJHS)] is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an open-access journal distributed under the terms of the Creative Commons Attribution License (CC BY-NC 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or name of the journal is credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Click here to get help about article submission processes and "Copyright Transfer Form".